TRIUMPH-4 Explained: Two Diabetes Specialists Break Down the Data

Our Take

What this episode covers

• The headline TRIUMPH-4 result: at 68 weeks, the 12 mg dose produced an average 28.7% weight loss (71.2 lbs), the 9 mg dose produced 26.4%, versus 2.1% for placebo — in participants whose average starting BMI was 40.
• The osteoarthritis angle — how the trial measured knee-pain improvement using the WOMAC pain scale, not just weight.
• Cardiovascular risk markers that improved alongside weight loss.
• Why the hosts describe the magnitude of weight reduction as unprecedented for a drug trial — and where they stay cautious.

Where this fits in the TRIUMPH program

TRIUMPH-4 is the osteoarthritis trial within Lilly's broader Phase 3 program. It was the first TRIUMPH readout to report (December 2025), ahead of TRIUMPH-1 (general obesity) and the diabetes-focused TRANSCEND trials. Each studies retatrutide in a different population, which is why the headline weight-loss figures vary between them.

For context, retatrutide remains investigational across all of these trials. Strong topline numbers are not the same as FDA approval, and the full TRIUMPH-4 dataset is still pending peer-reviewed publication — the hosts are discussing Lilly's topline announcement, not a final published paper.

Disclaimer

Retatrutide is an investigational drug. It is not approved by the FDA and is not legally available outside clinical trials. This page is informational and is not medical advice or an offer to sell.